Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Joan Kucera
September 15, 2023

Liked this post? Share with others!

Berlin, June 29, 2023 – Bayer today announced the two-year (96 weeks) topline results of the pivotal clinical trial PHOTON investigating its novel aflibercept 8 mg with extended dosing regimens of up to 24 weeks in diabetic macular edema (DME) compared to the current standard of care EyleaTM (aflibercept 2 mg) with fixed intervals of 8 weeks…
Read More

Subscribe to our newsletter

Collect visitor’s submissions and store it directly in your Elementor account, or integrate your favorite marketing & CRM tools.

Do you want to boost your business today?

This is your chance to invite visitors to contact you. Tell them you’ll be happy to answer all their questions as soon as possible.

Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Subscribe to our newsletter

Do you want to boost your business today?

Learn how we helped 100 top brands gain success